MedTrace Logo

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

NCT00584948 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.

Conditions

  • Fragile X-Associated Tremor/Ataxia Syndrome
  • Fragile X Premutation Carriers

Interventions

DRUG

Memantine

Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.

DRUG

Placebo

Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Forest Laboratories

    collaborator INDUSTRY

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Randi J Hagerman, MD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584948 on ClinicalTrials.gov